BERNENGO, Maria Grazia

BERNENGO, Maria Grazia  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 139 (tempo di esecuzione: 0.049 secondi).
Titolo Data di pubblicazione Autore(i) File
1975-2011 Overall Survival, Disease Free Survival and Survival after Recurrence across gender in melanoma patients: what has changed? 2012 Simone Ribero; Pietro Quaglino; Martina Sanlorenzo; Simona Osella-Abate; Federica Marenco; Tiziana Nardò; Giuseppe Macripò; Maria Teresa Fierro; Maria Grazia Bernengo
Activity and safety of bexarotene as maintainance therapy in advanced/aggressive CTCL patients with stable disease or remission after systemic treatment: an observational multicenter trial from the GILC 2007 Pietro Quaglino; Maria Grazia Bernengo
Activity and safety of Bexarotene as maintenance therapy in CTCL patients (Mycosis Fungoides stage IIB-IV, Sezary Syndrome, peripheral T-cell lymphoma) with stable disease or remission after systemic treatments: A prospective multicenter trauil from the Italian Group of Cutaneous Lymphoma (GILC) 2011 Quaglino P;Pimpinelli N; Alaibac M; Quintini G; Bernengo MG
Alemtuzumab for the treatment of Sézary sindrome: clinical and immunological findings in 10 patients. 2006 Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Fierro MT.
Alterazioni funzionali e fenotipiche dei polimorfonucleati nei pazienti affetti da dermatite atopica 2011 Banche G; Allizond V; Novelli M; Fierro MT; Mandras N; Murabito P; Quaglino P; Scalas D; Merlino C; Roana J; Tullio V; Bernengo MG; Cuffini AM
Alterazioni funzionali e fenotipiche dei polimorfonucleati nella sindrome di sezary 2009 G. Banche; M.T. Fierro; M. Novelli; V. Allizond; A. Comessatti; P. Quaglino; D. Scalas; C. Merlino; M.G. Bernengo; A Cuffini
Associazione di ciclofosfamide, vincristina e prednisone (COP) nel trattamento dei linfomi cutanei: 20 anni di follow-up. 1996 Fierro MT; Verrone A; Savoia P; Quaglino P; Doveil GC; Bernengo MG
Biological prognostic factors in advanced metastatic melanoma patients treated with chemoimmunotheraphy. 1997 Fierro MT; Quaglino P; Lisa F; Savoia P; Bernengo MG
Bullous pemphigoid is characterised by a reduction of skin-homing/circulating FOXP3+ Tregs and by a down-regulation of the IL-10 pathway 2012 Quaglino P; Antiga E; Novelli M; Nardò T; Fava P; Ponti R; Osella-Abate S; Caproni M; Fabbri P; Bernengo MG
Butyric acid effects on melanoma cell lines: apoptosis induction and cell cycle cytofluorimetric evaluation 1999 Salomone B; Cambieri I; Ponti R; Lisa F; Osella-Abate S; Ugazio E; Gasco M; Bernengo MG.
Caratterizzazione immunoistochimica e citofluorimetrica di una nuova linea di melanoma. 1998 Salomone B; Osella-Abate S; Fierro MT; Bernengo MG
Un caso di linfoma B della cute plurirecidivato trattato con anticorpo monoclonale anti-CD20 (Rituximab). 2000 Fierro MT; Salomone B; Savoia P; Barberis M; Bernengo MG
Un caso di melanoma primitivo della mucosa esofagea. 2012 Sanlorenzo M; Marenco F; Ribero S; Savoia P; Quaglino P; Bernengo MG
CD26 (DPP-IV)- A useful marker in Sezary sindrome 1994 Novelli M; Fierro MT; Quaglino P; Lisa F; Doveil GC; Bernengo MG
CD26 expression on keratinocytes in normal skin, inflammatory skin diseases and cutaneous T-cell lymphomas (CTCL). 1995 Savoia P; Fierro MT; Novelli M; Verrone A; Quaglino P; Bernengo MG
CD26 expression on keratinocytes in normal skin, inflammatory skin diseases and cutaneous T-cell lymphomas (CTCL). 1995 Savoia P; Fierro MT; Novelli M; Verrone A; Quaglino P; Bernengo MG
CD3-CD56+ primary pure cutaneous lymphoma: a distinct entity in the spectrum of CD56 malignancies. 1996 Savoia P; Fierro MT; Novelli M; Verrone A; Quaglino P; Bernengo MG
CD4+CD26- evaluation is a more useful diagnostic parameter than CD4+CD7- in Sézary syndrome (SS). 1995 Novelli M; Quaglino P; Fierro MT; Savoia P; De Matteis A; Bernengo MG
CD4+CD26- evaluation is a more useful diagnostic parameter than CD4+CD7- in Sézary syndrome (SS). 1995 Novelli M; Quaglino P; Fierro MT; Savoia P; De Matteis A; Bernengo MG
Cell proliferation and DNA content in primary cutaneous B-cell lymphomas. 1999 Cambieri I; Ponti R; Quaglino P; Novelli M; Fierro MT; Bernengo MG